Published in J Clin Oncol on August 15, 2002
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med (2011) 2.32
Radiation and breast cancer: a review of current evidence. Breast Cancer Res (2004) 2.12
Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys (2008) 1.95
Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma (2011) 1.69
Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.46
The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol (2015) 1.40
Genetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study. PLoS One (2015) 1.38
Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol (2013) 1.21
Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med (2012) 1.20
A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol (2007) 1.20
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med (2010) 1.13
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet (2013) 1.10
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood (2005) 1.09
Beliefs about cancer causation and prevention as a function of personal and family history of cancer: a national, population-based study. Psychooncology (2008) 1.08
Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica (2009) 1.07
Secondary malignancies across the age spectrum. Semin Radiat Oncol (2010) 1.04
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model (2011) 1.01
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer (2009) 0.98
Second primary malignancies after treatment for malignant lymphoma. Br J Cancer (2005) 0.97
Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol (2010) 0.96
Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys (2007) 0.95
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol (2014) 0.94
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet (2007) 0.93
Second primary breast cancer after Hodgkin's disease. Br J Cancer (2004) 0.93
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol (2011) 0.93
Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol (2013) 0.92
Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys (2008) 0.92
Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol (2011) 0.91
Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open (2015) 0.91
Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study. BMC Cancer (2012) 0.90
The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer (2009) 0.88
Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer (2008) 0.87
The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr (2013) 0.86
Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol (2013) 0.86
Effect of organ size and position on out-of-field dose distributions during radiation therapy. Phys Med Biol (2010) 0.86
Treating prostate cancer with radiotherapy. Nat Rev Clin Oncol (2010) 0.86
Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses. Med Phys (2015) 0.86
Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study. Ann Oncol (2012) 0.84
Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. Hematol Oncol Clin North Am (2014) 0.84
Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis. Lung (2012) 0.84
Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer (2010) 0.83
High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. Br J Cancer (2006) 0.83
Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers. Leuk Lymphoma (2012) 0.82
Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications. Insights Imaging (2015) 0.82
The effect of patient characteristics on second primary cancer risk in France. BMC Cancer (2014) 0.81
Malignant Triton Tumor of the Sciatic Nerve as a Secondary Malignancy after Extended Field Radiotherapy and Chemotherapy of Hodgkin's Disease. Case Rep Oncol (2014) 0.78
Implementation of an analytical model for leakage neutron equivalent dose in a proton radiotherapy planning system. Cancers (Basel) (2015) 0.78
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys (2012) 0.78
The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma. Mediterr J Hematol Infect Dis (2014) 0.77
Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med (2015) 0.77
Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy. Int J Radiat Oncol Biol Phys (2016) 0.77
Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study. Oncol Lett (2011) 0.76
Modeling age-dependent radiation-induced second cancer risks and estimation of mutation rate: an evolutionary approach. Radiat Environ Biophys (2014) 0.76
Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma. Br J Cancer (2008) 0.75
Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study. Int J Cancer (2017) 0.75
Co-occurrence of Papillary and Follicular Thyroid Carcinoma in a Patient with Hodgkin's Disease. Turk J Haematol (2013) 0.75
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. Cancer (2013) 0.75
The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med (2015) 0.75
Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica (2014) 0.75
Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis. Contemp Oncol (Pozn) (2013) 0.75
Primary melanoma of the prostate: case report and review of the literature. BMC Urol (2015) 0.75
Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary? Cancer Med (2016) 0.75
Second malignancies in Hodgkin's disease: A review of the literature and report of a case with a secondary Lennert's lymphoma. J Oral Maxillofac Pathol (2014) 0.75
Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report. Case Rep Oncol (2012) 0.75
Lung cancer and concurrent or sequential lymphoma: Two case reports with hypersensitivity to bevacizumab and a review of the literature. Oncol Lett (2014) 0.75
Secondary cancer in a survivor of Hodgkin's lymphoma: A case report and review of the literature. Oncol Lett (2014) 0.75
Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients. J Thorac Dis (2012) 0.75
Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. Br J Cancer (2017) 0.75
Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History. J Clin Oncol (2017) 0.75
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]. Pathologe (2006) 0.75
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol (2009) 5.86
Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol (2002) 5.81
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 5.75
Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst (2006) 4.91
Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol (2005) 4.76
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg (2007) 4.22
Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet (2005) 4.15
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med (2007) 3.97
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst (2006) 3.90
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Physical activity and breast cancer: a systematic review. Epidemiology (2007) 3.90
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst (2003) 3.67
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst (2007) 3.55
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
Nitrate in public water supplies and the risk of colon and rectum cancers. Epidemiology (2003) 3.39
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood (2011) 3.30
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol (2003) 3.24
Anaplastic large-cell lymphoma in women with breast implants. JAMA (2008) 3.23
Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst (2010) 3.23
Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet (2003) 3.22
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 3.22
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst (2008) 3.13
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology (2002) 3.00
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol (2009) 2.93
Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol (2005) 2.91
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2005) 2.80
A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A (2006) 2.78
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2005) 2.76
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer (2006) 2.73
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2006) 2.71
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer (2002) 2.70
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2003) 2.68
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood (2010) 2.58
Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology (2005) 2.56
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst (2009) 2.55